114 results about "Anaplasma phagocytophilum" patented technology

The invention provides a staphylococcus aureus phage strain VB_SavM_JYL01. The staphylococcus aureus phage stain VB_SavM_JYL01 has been preserved in the China Center for Type Culture Collection on 25th March, 2018, the preservation name is Staphylococcus aureus phage VB_SavM_JYL01, and the preservation number is CCTCC M 2018154. The staphylococcus aureus phage strain has a wide lysis spectrum, thus staphylococcus aureus can be lysed, certain staphylococcus epidermidis can also be lysed, host bacteria 206 can be lysed, and staphylococcus clinical strains separated from the environment or fecesof diseased animals can also be lysed; the staphylococcus aureus phage can be used independently or in combination with other substances, and a safe and nontoxic phage disinfecting and killing productis provided for disinfecting and purifying the environment.

The invention provides a humanized neutralizing antibody D5 against the avian influenza virus (AIV) H7N9. The neutralizing antibody D5 is screened by utilizing the phage surface display technique. The amino acid sequences of light and heavy chain variable regions of the neutralizing antibody D5 are respectively shown in SEQ ID No.1 and SEQ ID No.2. The antibody can specifically recognize the antigens of H7N9 virions, can carry out obvious enzyme-linked immunosorbent assay with the virus H7N9, and has a neutralizing activity function of resisting infection with the virus H7N9. Besides, the antibody can be used for preparing specific antibody drugs for preventing and treating the AIV H7N9, and then the drugs are clinically used for preventing and treating acute respiratory infectious diseases caused by the virus H7N9.

Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.

The present invention relates to a composition comprising the bacteriophage EK88P-1 isolated from the nature and having a broad antibacterial spectrum against E. coli as an active ingredient, and a method for preventing and treating E. coli infections using the said composition. The bacteriophage EK88P-1, the active ingredient of the composition of the present invention, has a broad antibacterial spectrum against E. coli and has the genome characteristically composed of the partial nucleotide sequences represented by SEQ ID NO: 1 to SEQ ID NO: 25, and also characterized by the bacteriophage belonging to the Myoviridae family according to the morphology that is composed of the major structural proteins in the sizes of approximately 49 kDa, 53 kDa, 94 kDa, and 103 kDa.

The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba / F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC / Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.

The invention relates to the technical field of antibody engineering and in particular discloses a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) resistant monoclonal antibody. The monoclonal antibody disclosed by the invention comprises an amino acid sequence coding an antibody variable region and a CDR region. The invention further discloses an acquiring method and application of the monoclonal antibody. The method comprises the following steps: screening a PCSK9 resistant monoclonal antibody from a phage antibody library, performing affinity maturation through a method for constructing the phage antibody library by virtue of strand displacement, performing mutant library-construction screening on light-chain CDR1, 2 and 3 regions of the monoclonal antibody obtained by preliminaryscreening, selecting a monoclonal antibody with high affinity, performing mutant library-construction screening on heavy-chain CDR1, 2 and 3 regions of the monoclonal antibody, and finally screeningthe PCSK9 resistant monoclonal antibody with high affinity. The PCSK9 resistant monoclonal antibody obtained in the invention has excellent affinity to PCSK9, is capable of inhibiting binding betweenthe PCSK9 and ligands thereof, and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombosis-obstructive diseases.